Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences Jun 11, 2025 08:30AM
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth Sep 4, 2024 09:15AM
BNTX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action – BNTX Mar 7, 2024 03:09PM
BNTX DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action – BNTX Mar 3, 2024 03:14PM
BNTX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action – BNTX Feb 27, 2024 07:49PM
View Older Stories

Feb 16, 2024 05:03PM ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – BNTX
Feb 11, 2024 08:01AM ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action – BNTX
Feb 8, 2024 05:34PM ROSEN, A RANKED AND LEADING FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action – BNTX
Jan 26, 2024 01:19PM ROSEN, A LEADING LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action – BNTX
Jan 17, 2024 05:32PM ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages BioNTech SE Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – BNTX
Oct 26, 2023 06:45AM Pfizer (PFE) and BioNTech (BNTX) Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
Oct 26, 2023 06:45AM Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
Sep 11, 2023 01:50PM Pfizer (PFE) and BioNTech (BNTX) Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine
Sep 11, 2023 01:50PM Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine
Dec 9, 2022 06:47AM BioNTech SE (BNTX), Pfizer (PFE) Granted FDA Fast Track Designation for Single-Dose mRNA-Based COVID Vaccine
Dec 9, 2022 06:45AM Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza
Dec 9, 2022 06:45AM Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza
Dec 8, 2022 10:43AM Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years
Dec 8, 2022 10:40AM Pfizer (PFE) and BioNTech (BNTX) Receive U.S. FDA EUA for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years
Dec 8, 2022 10:39AM Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years
Dec 8, 2022 10:39AM Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years
Nov 30, 2022 01:02AM BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates
Nov 18, 2022 06:46AM BioNTech SE (BNTX) and Pfizer (PFE) Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster
Nov 18, 2022 06:45AM Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages
Nov 18, 2022 06:45AM Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages
Nov 17, 2022 05:53AM BioNTech SE (BNTX) and Pfizer (PFE) Advance Next-Generation COVID-19 Vaccine Strategy
Nov 16, 2022 06:30PM Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection
Nov 16, 2022 06:30PM Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection
Nov 10, 2022 09:45AM Pfizer (PFE) and BioNTech (BNTX) Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in EU
Nov 10, 2022 09:45AM Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union
Nov 10, 2022 09:45AM Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union
Nov 4, 2022 06:50AM Pfizer (PFE) and BioNTech (BNTX) Report Strong Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster
Nov 4, 2022 06:48AM Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine
Nov 4, 2022 06:48AM Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine
Nov 4, 2022 06:47AM Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine
Oct 19, 2022 11:46AM Pfizer (PFE) and BioNTech (BNTX) Receive Positive CHMP Opinion for COMIRNATY in Children 6 Months to less than 5 Years in the European Union
Oct 19, 2022 11:45AM Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY® in Children 6 Months to less than 5 Years in the European Union
Oct 19, 2022 11:45AM Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY® in Children 6 Months to less than 5 Years in the European Union
Oct 13, 2022 06:47AM BioNTech SE (BNTX) and Pfizer (PFE) Report Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster
Oct 13, 2022 06:45AM Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older
Oct 13, 2022 06:45AM Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older
Oct 13, 2022 06:45AM Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older
Oct 12, 2022 10:30AM Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age
Oct 12, 2022 10:30AM Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age
Oct 12, 2022 10:16AM Pfizer (PFE), BioNTech (BNTX) Confirm U.S. FDA EUA for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age
Oct 12, 2022 10:16AM Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age
Sep 26, 2022 06:45AM BioNTech SE (BNTX) and Pfizer (PFE) Submit FDA Application for EMA of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children Aged 5-11
Sep 26, 2022 06:45AM Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age
Sep 26, 2022 06:45AM Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age
Sep 26, 2022 06:45AM Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age
Sep 16, 2022 08:00AM Pfizer (PFE), BioNTech (BNTX) Receive Positive CHMP Opinion for Conversion of COMIRNATY® Conditional Marketing Authorization to Full Marketing Authorization in the European Union
Sep 16, 2022 08:00AM Pfizer and BioNTech Receive Positive CHMP Opinion for Conversion of COMIRNATY® Conditional Marketing Authorization to Full Marketing Authorization in the European Union
Sep 16, 2022 08:00AM Pfizer and BioNTech Receive Positive CHMP Opinion for Conversion of COMIRNATY® Conditional Marketing Authorization to Full Marketing Authorization in the European Union
Sep 12, 2022 11:20AM Pfizer (PFE), BioNTech (BNTX) Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union
Sep 12, 2022 11:20AM Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union
View Older Stories